Microtubule-associatedproteins1A/1Blightchain3B / Autophagy-related protein LC3 B / Autophagy-related ubiquitin-like modifier LC3 B / MAP1 light ...Autophagy-related protein LC3 B / Autophagy-related ubiquitin-like modifier LC3 B / MAP1 light chain 3-like protein 2 / MAP1A/MAP1B light chain 3 B / MAP1A/MAP1B LC3 B / Microtubule-associated protein 1 light chain 3 beta
Optineurin / E3-14.7K-interacting protein / FIP-2 / Huntingtin yeast partner L / Huntingtin-interacting protein ...E3-14.7K-interacting protein / FIP-2 / Huntingtin yeast partner L / Huntingtin-interacting protein 7 / HIP-7 / Huntingtin-interacting protein L / NEMO-related protein / Optic neuropathy-inducing protein / Transcription factor IIIA-interacting protein / TFIIIA-IntP
分子量: 2245.813 Da / 分子数: 1 / 断片: UNP RESIDUES 169-185 / 由来タイプ: 合成 / 詳細: The peptide was chemically synthesized. / 由来: (合成) Homo sapiens (ヒト) / 参照: UniProt: Q96CV9
-
実験情報
-
実験
実験
手法: 溶液NMR 詳細: Complex structure of the autophagy modifier LC3B with synthetic OPTN-LIR peptide in totally phosphorylated form (all five serines are phosphoserines)
NMR実験
Conditions-ID
Experiment-ID
Solution-ID
タイプ
1
1
1
2D 1H-15N HSQC
1
2
1
2D 1H-13C HSQC
1
3
1
2D 1H-13C HSQC aromatic
1
4
1
3D HN(CA)CB
1
5
1
3D HNCO
1
6
1
3D (H)CCH-TOCSY
1
7
1
3D 1H-15N NOESY
1
8
1
3D 1H-13C NOESY aliphatic
1
9
1
3D 1H-13C NOESY aromatic
1
10
1
3D NOESY-[13C,1H]-HSQC 13C/15N filtered in F1
1
11
2
2D 1H-1H NOESY F1,F2 13C/15N filtered
1
12
1
3D NOESY-[15N,1H]-FHSQC
-
試料調製
詳細
Solution-ID
内容
溶媒系
1
0.6 mM [U-98% 13C; U-98% 15N] entity_1-1, 4.9 mM entity_2-2, 70 mM sodium phosphate-3, 30 mM sodium chloride-4, 0.3 mM DSS-5, 5 mM Protease inhibitors cocktail-6, 95% H2O/5% D2O
95% H2O/5% D2O
2
2.5 mM [U-98% 13C; U-98% 15N] entity_1-7, 0.4 mM entity_2-8, 70 mM sodium phosphate-9, 30 mM sodium chloride-10, 0.3 mM DSS-11, 5 mM Protease inhibitors cocktail-12, 95% H2O/5% D2O
95% H2O/5% D2O
試料
濃度 (mg/ml)
構成要素
Isotopic labeling
Solution-ID
0.6mM
entity_1-1
[U-98% 13C; U-98% 15N]
1
4.9mM
entity_2-2
1
70mM
sodium phosphate-3
1
30mM
sodium chloride-4
1
0.3mM
DSS-5
1
5mM
Protease inhibitors cocktail-6
1
2.5mM
entity_1-7
[U-98% 13C; U-98% 15N]
2
0.4mM
entity_2-8
2
70mM
sodium phosphate-9
2
30mM
sodium chloride-10
2
0.3mM
DSS-11
2
5mM
Protease inhibitors cocktail-12
2
試料状態
イオン強度: 0.05 / pH: 6.8 / 圧: ambient / 温度: 288 K
-
NMR測定
NMRスペクトロメーター
タイプ
製造業者
モデル
磁場強度 (MHz)
Spectrometer-ID
Bruker Avance
Bruker
AVANCE
900
1
Bruker Avance
Bruker
AVANCE
800
2
Bruker Avance
Bruker
AVANCE
700
3
Bruker Avance
Bruker
AVANCE
600
4
Bruker Avance
Bruker
AVANCE
500
5
-
解析
NMR software
名称
バージョン
開発者
分類
TopSpin
2
BrukerBiospin
collection
TopSpin
2
BrukerBiospin
chemicalshiftcalculation
TopSpin
2
BrukerBiospin
解析
Sparky
3.114
Goddard
データ解析
Sparky
3.114
Goddard
chemicalshiftassignment
Sparky
3.114
Goddard
peakpicking
CYANA
2
Guntert, MumenthalerandWuthrich
構造決定
OPALp
Koradi, BilleterandGuntert
精密化
精密化
手法: restrained energy refinement / ソフトェア番号: 1
NMR constraints
NOE constraints total: 3472 / NOE intraresidue total count: 750 / NOE long range total count: 1240 / NOE medium range total count: 715 / NOE sequential total count: 767 / Hydrogen bond constraints total count: 94 / Protein phi angle constraints total count: 126 / Protein psi angle constraints total count: 130
代表構造
選択基準: closest to the average
NMRアンサンブル
コンフォーマー選択の基準: structures with the lowest energy 計算したコンフォーマーの数: 100 / 登録したコンフォーマーの数: 20 / Maximum upper distance constraint violation: 0.1 Å / 代表コンフォーマー: 2